Info

PolyMedix, Inc. is a biotechnology company focused on treating infectious diseases and acute cardiovascular disorders with synthetic small molecule compounds that mimic the activity of natural protein molecules, compounds referred to as biomimetics. Using the Company’s computational drug design technology, it has created defensin mimetic antibiotic compounds, heparin antagonist compounds (or heptagonist) and other drug compounds intended for human therapeutic use. The Company has developed PMX-30063, its principal defensin mimetic antibiotic product candidate, and other small molecule defensin mimetic antibiotics that mimic the activity of host defense proteins. It is seeking to commercialize these defensin mimetic compounds as antibiotics in a variety of forms to combat drug-resistant bacterial infections.(Source: 10-K)